Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
Éric Raymond(Hôpital Paris Saint-Joseph), Martin J. van den Bent(Erasmus MC Cancer Institute), Christian Dittrich(Leibniz Institute for Agricultural Engineering and Bioeconomy), P. Fumoleau(Institut Curie), Bruno Coudert(Ludwig Boltzmann Institute for Cancer Research), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Roger Stupp(Northwestern University), R. Rampling(Cancer Research UK), Johan M. Kros(Erasmus MC), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Michael C. Heinrich(VA Portland Health Care System), Paul M. Clément(Universitair Ziekenhuis Leuven), Denis Lacombe(European Organisation for Research and Treatment of Cancer), Marc Frénay(Ludwig Boltzmann Institute for Cancer Research)
Cited by 226
Related Papers
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k